Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: A meta-analysis of randomized controlled trials

HIV Medicine

Volumn 9, Issue 9, 2008, Pages 747-756

  Ena, Javier ^a   Leach, A ^a   Nguyen, P ^a  

^a HOSPITAL MARINA BAIXA   (Spain)

Author keywords

Antiretroviral therapy highly active; Meta analysis; Nevirapine; Protease inhibitors

Indexed keywords

AMPRENAVIR PLUS RITONAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SAQUINAVIR PLUS RITONAVIR; UNCLASSIFIED DRUG;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBASE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER FUNCTION TEST; LIVER TOXICITY; MEDLINE; META ANALYSIS; MIXED INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SYSTEMATIC REVIEW; VIRUS INHIBITION; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIVER; MALE; MIDDLE AGED; NEVIRAPINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 54049090424     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00627.x     Document Type: Article

References (40)

1. Mallal S, Nolan E, Witt C et al. Association between the presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
2. Rauch A, Nolan D, Martin A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity in the Western Australian HIV Cohort Study. Clin Infect Dis 2006; 43: 99-102.
3. Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-1260.
4. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-1046.
5. Martinez E, Arnaiz JA, Podzamczer D et al. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS 2007; 21: 367-369.
6. Rihs TA, Begley K, Smith DE et al. Efavirenz and chronic neuropsychiatric symptoms: A cross-sectional case control study. HIV Med 2006; 7: 544-548.
7. Boly L, Cafaro V, Dyner T. Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J Acquir Immune Defic Syndr 2006; 42: 514-515.
8. Jover F, Cuadrado JM, Roig P, Rodriguez M, Andreu L, Merino J. Efavirenz-associated gynecomastia: Report of five cases and review of the literature. Breast J 2004; 10: 244-246.
9. van Leth F, Phanuphak P, Stroes E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. PLoS Med 2004; 1: E19.
10. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
11. Gil P, de Gorgolas M, Estrada V et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis 2004; 39: 1024-1029.
12. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-810.
13. Fisac C, Fumero E, Crespo M et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19: 917-925.
14. Tebas P, Yarasheski K, Henry K et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20: 589-594.
15. Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003; 14: 776-781.
16. Law WP, Dore GJ, Duncombe CJ et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17: 2191-2199.
17. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002; 35: 182-189.
18. Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-129.
19. Bourezanne Y, Salard D, Hoen B, Vandel S, Drobasheff C, Laurent R. DRESS (Drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998; 27: 1321-1322.
20. Boehringer-Ingelheim: http://www.Boehringer-ingelheim.com/hiv/prod/ login.htm. Accessed 20 July, 2007.
21. Moher D, Cook DJ for the QUOROM Group et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM Statement. Lancet 1999; 354: 1896-1900.
22. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
23. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
25. Arranz Caso JA, Lopez JC, Santos I et al. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. HIV Med 2005; 6: 353-359.
26. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14: 807-812.
27. Calza L, Manfredi R, Colangeli V et al. Substitution of nevirapine or efavirenz for protease inhibitor vs. lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005; 19: 1051-1058.
28. Negredo E, Ribalta J, Paredes R et al. Reversal of atherogenic lipoprotein profile in HIV-1-infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16: 1383-1389.
29. Negredo E, Cruz L, Paredes R et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34: 504-510.
30. Ruiz L, Negredo E, Domingo P et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001; 27: 229-236.
31. Bucher HC, Kofler A, Nüesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomized controlled trials of simplified vs. continued protease-inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003; 17: 2451-2459.
32. Martínez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
33. Bonnet F, Lawson-Ayayi S, Thiébaut R et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis 2002; 35: 1231-1237.
34. Maggiolo F, Arici C, Airoldi M et al. Reasons for discontinuation of nevirapine-containing HAART: Results from an unselected population of a large clinical cohort. J Antimicrob Chemother 2007; 59: 569-572.
35. Mocroft A, Staszewski S, Weber R et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naïve and -experienced HIV-infected patients with high and low CD4 T-cell counts. Antivir Ther 2007; 12: 325-333.
36. Kumarasamy N, Venkatesh KK, Devaleenal B et al. Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. J Acquir Immune Defic Syndr 2007; 45: 598-600.
37. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006; 8: 191-203.
38. Casado A, Badia X, Consiglio E et al. Health-related quality of life in HIV-infected naïve patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy). HIV Clin Trials 2004; 5: 132-139.
39. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1-infected adults. AIDS 2001; 15: 1369-1377.
40. The European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use: Points to consider on the choice of non-inferiority margin. http://www.emea.eu.int/pdfs/human/ewp/ 215899en.pdf. Accessed 4 June 2006.